EU-UK trade deal continues to hurt trade with 27% drop in exports since 2021 reports Aston University
UK’s post-Brexit checks on fruit and vegetables delayed for a third time
Here’s Peter Foster, the FT’s public policy editor, on today’s UK-EU trade report:
Today’s report into UK-EU trade shows how Britain’s pharmaceuticals industry has suffered from regulatory divergence issues since Brexit.
For instance, while the mutual recognition of production certificates is agreed in the TCA [the Trade and Cooperation Agreement, or Brexit deal], the EU no longer recognises medicine batches tested in the UK as valid for sale within the single market, nor does it recognise the professionals overseeing these processes.
UK pharmaceutical firms now require separate certifications for both the UK and EU markets, resulting in increased costs and delays.
About Author
More Stories
Leading tax expert calls out ‘confected outrage’ of wealthy Australians over Labor’s $3m super plan
KFC plans to invest £1.5bn in UK and Ireland, creating thousands of jobs
Shein turns to Hong Kong for flotation as London attempt stalls, reports say